Aldeyra Therapeutics (NASDAQ:ALDX) and Grifols (NASDAQ:GRFS) Head to Head Comparison

Aldeyra Therapeutics (NASDAQ:ALDX) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Volatility & Risk

Aldeyra Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Profitability

This table compares Aldeyra Therapeutics and Grifols’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-63.75%	-41.27%
Grifols	6.65%	6.23%	2.40%

Earnings & Valuation

This table compares Aldeyra Therapeutics and Grifols”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85 million	($0.57)	-3.12
Grifols	$8.51 billion	0.66	$565.70 million	$0.19	43.21

Grifols has higher revenue and earnings than Aldeyra Therapeutics. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Aldeyra Therapeutics and Grifols, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1	2	1	0	2.00
Grifols	1	3	0	0	1.75

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 208.99%. Grifols has a consensus price target of $10.00, suggesting a potential upside of 21.80%. Given Aldeyra Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Grifols.

Institutional and Insider Ownership

59.7% of Aldeyra Therapeutics shares are held by institutional investors. 8.5% of Aldeyra Therapeutics shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Grifols beats Aldeyra Therapeutics on 7 of the 13 factors compared between the two stocks.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.